# 68Ga-THP-PSMA PET/CT Imaging in High Risk Primary Prostate Cancer or Biochemical Recurrence of Prostate Cancer

> **NCT03617588** · PHASE2 · COMPLETED · sponsor: **Theragnostics Ltd** · enrollment: 49 (actual)

## Conditions studied

- Prostate Cancer

## Interventions

- **DRUG:** Gallium-68 THP-PSMA

## Key facts

- **NCT ID:** NCT03617588
- **Lead sponsor:** Theragnostics Ltd
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2018-06-18
- **Primary completion:** 2019-06-12
- **Final completion:** 2019-06-12
- **Target enrollment:** 49 (ACTUAL)
- **Last updated:** 2020-06-24


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03617588

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03617588, "68Ga-THP-PSMA PET/CT Imaging in High Risk Primary Prostate Cancer or Biochemical Recurrence of Prostate Cancer". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT03617588. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*